Claire Corcoran - Concepedia

Author

Claire Corcoran

Trinity College Dublin

Also Known As

C Corcoran, C. Corcoran, C. P. Corcoran, Christian Corcoran, Claire Corcoran, G Briguglio

108

Publications

3.5K

Citations

H-Index

Concepts

All Affiliations

Trinity College Dublin AstraZeneca (United Kingdom)Dublin City University Institute of Cancer Research Peter MacCallum Cancer Centre

About

Claire Corcoran is an author at Trinity College Dublin specializing in medicine, oncology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	139
2	Pathology	4	4	95
3	Molecular Medicine	2	2	38
4	Cell Biology	1	1	44
5	Pharmacology	1	1	44

Claire Corcoran

Publications

3.1K

Citations

H-Index

Page 1

	Year	Citations
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer Maha Hussain, Joaquı́n Mateo, Karim Fizazi, New England Journal of Medicine	2020	734
Docetaxel-Resistance in Prostate Cancer: Evaluating Associated Phenotypic Changes and Potential for Resistance Transfer via Exosomes Claire Corcoran, Sweta Rani, Keith O’Brien, PLoS ONE	2012	433
miR-134 in extracellular vesicles reduces triple-negative breast cancer aggression and increases drug sensitivity Keith O’Brien, Michelle C. Lowry, Claire Corcoran, Oncotarget	2015	268
Characterisation and manipulation of docetaxel resistant prostate cancer cell lines Amanda O’Neill, Maria Prencipe, Catherine Dowling, Molecular Cancer	2011	246
Exosomes from triple-negative breast cancer cells can transfer phenotypic traits representing their cells of origin to secondary cells Keith O’Brien, Sweta Rani, Claire Corcoran, European Journal of Cancer	2013	239
miR‐34a is an intracellular and exosomal predictive biomarker for response to docetaxel with clinical relevance to prostate cancer progression Claire Corcoran, Sweta Rani, Lorraine O’Driscoll The Prostate	2014	218
Optimised Pre-Analytical Methods Improve KRAS Mutation Detection in Circulating Tumour DNA (ctDNA) from Patients with Non-Small Cell Lung Cancer (NSCLC) James Sherwood, Claire Corcoran, Helen Brown, PLoS ONE	2016	145
A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in <i>PIK3CA</i> -Mutated Breast and Gynecologic Cancers Udai Banerji, Emma Dean, José Alejandro Pérez Fidalgo, Clinical Cancer Research	2017	139
Isolation of Exosomes for Subsequent mRNA, MicroRNA, and Protein Profiling Sweta Rani, Keith O’Brien, Fergal C. Kelleher, Methods in molecular biology	2011	108
Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with <i>AKT1</i> E17K-Mutant, ER-Positive Metastatic Breast Cancer Lillian M. Smyth, Kenji Tamura, Mafalda Oliveira, Clinical Cancer Research	2020	97

Page 1